Bedrijfsoverzicht
Aytu BioPharma, Inc. is a pharmaceutical entity dedicated to the commercialization of novel therapeutics within the United States and international markets, with a specific focus on prescription products for conditions such as attention deficit hyperactivity disorder (ADHD), including the extended-release orally disintegrating formulation Adzenys XR-ODT. The company operates within the Healthcare sector, specifically inside the Drug Manufacturers - Specialty & Generic industry, which characterizes its business model as the development and sale of specialized medical treatments rather than mass-market consumer goods. According to available financial data, the company possesses a market capitalization of $27.37M, generates annual revenue of $62.64M, and employs 82 individuals to execute its operational strategy. These valuation and revenue figures indicate that Aytu BioPharma operates as a small-cap entity with a relatively modest revenue stream compared to large-cap pharmaceutical peers, suggesting a niche market position where growth is driven by the adoption of specific therapeutic products rather than broad market dominance. The low employee count relative to the revenue generated also points to a highly specialized or automated operational structure typical of niche drug manufacturers.
Financiële gezondheid
The company reported revenue of $62.64M over the trailing twelve months, accompanied by a net income of $-24,559,000 and an EBITDA of $4.03M. The substantial disparity between the positive EBITDA of $4.03M and the negative net income of $-24,559,000 reveals a significant cost structure burdened by non-operating expenses, such as interest payments or other corporate costs that are deducted after EBITDA is calculated. Free cash flow stands at $-6,978,375, indicating that the company is currently consuming cash reserves to fund its operations and development activities, which limits immediate financial flexibility for aggressive expansion or large-scale acquisitions. The margin profile presents a complex picture: the gross margin is 66.8%, reflecting high efficiency in production and pricing power for its core products, while the operating margin is -13.0% and the profit margin is -39.0%, demonstrating that high operational and non-operating costs are eroding profitability at the bottom line. Regarding leverage, the company holds $30.02M in cash against $22.10M in debt, resulting in a debt-to-equity ratio of 155.63%, which suggests a leveraged balance sheet where debt exceeds equity, a common feature in biopharmaceutical firms but one that requires careful cash management. Liquidity is assessed via a current ratio of 1.16, which indicates that the company has just enough current assets to cover its current liabilities, placing it in a neutral-to-tight liquidity position without excessive safety buffers. Finally, the return on equity is -109.2% and the return on assets is -0.2%, metrics that reveal that management has not been effective in generating positive returns on the capital invested by shareholders or the total asset base during the reported period.
Waarderingsbeoordeling
Valuation metrics for Aytu BioPharma show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is 15.00, implying that the market prices the stock based on projected future profitability rather than current historical performance. The price-to-book ratio is 1.93, indicating that the market values the company at nearly twice its book value, which suggests a premium assigned to the company's intangible assets, such as its drug pipeline and intellectual property, despite current earnings losses. Alternative valuation multiples include a price-to-sales ratio of 0.44 and an EV/EBITDA of 4.83, suggesting that the stock is priced at less than half of its annual sales, which can be attractive if future revenue growth materializes, though the low EV/EBITDA also reflects the company's current lack of profitability. The stock's trading range over the past year spans a high of $3.07 and a low of $0.98, meaning the current price sits somewhere within this wide band, reflecting significant price discovery volatility typical of small-cap biotech firms. The beta value of 0.28 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the general market index, which may appeal to investors seeking lower short-term price swings despite the inherent risks of the healthcare sector.
Growth & Income
Revenue growth year-over-year is -6.5%, while earnings growth year-over-year is N/A due to negative net income, implying that the company is currently in a contraction phase regarding top-line sales rather than an expansion phase. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders and instead retains all earnings to reinvest into research, development, and commercialization efforts. This strategy of zero dividends and negative revenue growth highlights a growth-at-any-cost approach where management prioritizes long-term product development over immediate income distribution to existing shareholders. The overall growth and income profile for Aytu BioPharma is characterized by negative revenue momentum and a complete absence of dividend income, positioning the asset purely as a speculative play on future therapeutic success rather than a value or income investment vehicle.